Pharma BD Deal Intelligence
Novartis bought BOOST/Isocal/Ultracal for $385M in 2004, then exited the entire Medical Nutrition unit to Nestlé for $2.5B just three years later—a good trade financially, but proof the diversification-into-nutrition thesis itself didn't stick.
Novartis bought BOOST/Isocal/Ultracal for $385M in 2004, then exited the entire Medical Nutrition unit to Nestlé for $2.5B just three years later — a good trade, but proof the diversification thesis itself didn't stick.
Full analysis, sources & comparables →Novartis is paying $385M cash, or 1.75x 2002 sales, to acquire Mead Johnson's adult medical-nutrition franchise and its anchor Boost, Isocal, and Ultracal…
Closing of the $385M Mead Johnson deal moves Novartis Medical Nutrition to roughly $815M in 2003 pro-forma sales and the No.2 global position in medical…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Novartis acquired Bristol-Myers Squibb's Mead Johnson adult medical nutrition business (Boost, Isocal, Ultracal brands) for $385M cash, roughly 1.75x the unit's 2002 sales of $220M; the transaction closed in March 2004. Remove the trailing 'Sources:' citation list from the summary body.
Novartis bought BOOST/Isocal/Ultracal for $385M in 2004, then exited the entire Medical Nutrition unit to Nestlé for $2.5B just three years later — a good trade, but proof the diversification thesis itself didn't stick.
Assessment window: 15yr post-close.
$815M Novartis Medical Nutrition global 2003 sales post-deal (USD)
Adult medical nutrition products (oral nutritional supplements and enteral tube-feeding formulas) support patients with cancer, dysphagia, malabsorption, post-surgical recovery, and frailty in long-term care. Demand is driven by aging demographics, hospital length-of-stay management, and reimbursement under Medicare Part B and institutional contracts.
In 2003, the US adult medical nutrition category was a roughly $2-3B market dominated by Abbott's Ross Products (Ensure, Glucerna, Jevity, Promote, Osmolite), Nestle's Novartis-acquired/legacy lines, and Mead Johnson/BMS (Boost, Isocal, Ultracal, Choice DM). Novartis Medical Nutrition (the buyer) already marketed Resource, Isosource, Novasource, Impact, and Compat brands, primarily in institutional settings (FoodNavigator, Dec 2003). The $385M cash deal at 1.75x 2002 sales of $220M brought Boost, Isocal, and Ultracal plus IP and the US retail-channel presence Novartis lacked, immediately taking Novartis Medical Nutrition to ~$815M global 2003 pro-forma sales and the No.2 worldwide position behind Abbott Ross (Novartis press release, Feb 17 2004). For BMS, the divestiture was part of a multi-year refocusing on biopharmaceuticals; Mead Johnson's pediatric/infant nutrition unit (Enfamil) was kept and ultimately spun off in 2009. Novartis itself later sold the Medical Nutrition unit to Nestle in 2007 for $2.5B, indicating substantial value creation off this 2003 build-out.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Mead Johnson Adult Medical Nutrition (BMS divestiture) (this deal) | 2003 | $385M | 63 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2003 deals · Novartis AG deals